Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 2Completed 1

Sponsor Class

NIH 3OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 5Ovarian Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Ovarian Epithelial 4Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Gliosarcoma 3Glioblastoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Brain Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1

Interventions

Melphalan 20Cyclophosphamide 17Dexamethasone 14Peripheral Blood Stem Cell Transplantation 12Filgrastim 9sargramostim 8fludarabine phosphate 7Interferon-alpha 7Busulfan 7Bortezomib 7Vincristine 6Thalidomide 6Prednisone 6Doxorubicin 5Antilymphocyte Serum 5Radiotherapy 4Cyclosporine 4Mycophenolic Acid 3Methylprednisolone 3Idarubicin 3Etoposide 3Drug Therapy 3Ascorbic Acid 3Arsenic Trioxide 3Rituximab 2Methotrexate 2Interleukin-12 Subunit p35 2Ifosfamide 2Cytarabine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Neoplasms, Plasma Cell × Drug Therapy × Clear all
NCT00416897 2013-08-26

Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure

National Cancer Institute (NCI)

Phase 3 Completed
280 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00085345 2013-07-10

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡